MedTrace Logo

PREcision Medicine in Cancer in Odense, Denmark

NCT05385081 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2022-05-23

No results posted yet for this study

Summary

The traditional approach to cancer treatment has changes from using drugs approved for the specific cancer diagnosis to a tumor agnostic approach when treating solid tumors. How often will tumor biopsy and genomic profiling in patients with advanced solid tumors with no further evidence based treatment options result in biomarker-driven targeted treatment ? Feasibility of the investigation of patients and median turnaround time from biopsy to available genomic profile is evaluated.

Conditions

  • Metastatic Solid Tumor

Interventions

OTHER

genomic profiling

next generation sequencing

Sponsors & Collaborators

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Karin H Hansen · Departement of Oncology Odense University Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05385081 on ClinicalTrials.gov